Immunohistochemical expression of p53 and MDM2 within head and neck squamous cell carcinoma

2006 ◽  
Vol 31 (3) ◽  
pp. 247-247 ◽  
Author(s):  
S. Tandon ◽  
H. Beer ◽  
T.M. Jones ◽  
M. Birchall ◽  
M. Boyd ◽  
...  
Author(s):  
Naila Umer ◽  
Nadia Naseem ◽  
Saima Chaudhry

Abstract Objective: To determine immunohistochemical expression of Mucin 4 in head and neck squamous cell carcinoma and its different histological grades among patients reporting to various tertiary care hospitals in an urban setting. Method: The descriptive study was conducted at the Department of Oral Pathology / Morbid Anatomy and Histopathology, University of Health Sciences, Lahore, Pakistan, from January to July 2017, and comprised cases of head and neck squamous cell carcinoma. Histological diagnosis and grading was done for each case. Haematoxylin and eosin stain followed by immunohistochemistry was done. Relation of Mucin 4 expression with tumour types was explored. SPSS 20 was used for statistical analysis. Result: Of the 63 samples, 40(63.5%) were from male patients. The overall mean age of the patients was 53±3.77 years. Mucin 4 expression was positive in 47(74.6%) cases. Of them, 16(34%) had grade 1 tumour, 28(59.6%) had grade 2 and 3(6.4%) had grade 3 tumour. tumourThere was a significant relation (p=0.03) between tumour grades and intensity of Mucin 4 expression. tumour Conclusion: Upregulation of Mucin 4in tumour tissue with no expression in normal epithelium was found, and loss of Mucin 4 expression with increase in tumour grade was noted. Key Words: Mucin 4, MUC4, Squamous cell carcinoma of head and neck, HNSCC, Immunohistochemistry Continuous...


2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e17016-e17016
Author(s):  
E. Saada ◽  
J. Thariat ◽  
F. Ettore ◽  
A. Sudaka ◽  
E. Chamorey ◽  
...  

e17016 Background: The overexpression of excision repair cross-complementation group 1 (ERCC1), element of the Nucleotid Excision Repair (NER) pathway has been associated with resistance to platinum-based chemotherapy. We studied the correlation of ERCC1 immunohistochemical expression with overall survival and cancer-specific survival in patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) treated with cisplatin-based chemotherapy. Methods: Using a monoclonal antibody against ERCC1 (clone 8F1, Neomarker), we analyzed its immunohistochemical expression in pretherapeutic samples of 142 HNSCC patients treated in our center from 2000 to 2006. Forty-three patients were treated with surgery followed by adjuvant radiochemotherapy, 86 with concomitant radiochemotherapy with or without neoadjuvant chemotherapy and 13 with cisplatin-based chemotherapy for metastatic disease. Two independent observers blinded to clinical data evaluated ERCC1 expression using the H-score protocol (ranging from 0 to 3). Survival rates were estimated using the Kaplan-Meier method. Survival univariate analysis was performed using log-Rank test. Results: ERCC1was expressed intensively and diffusely in the nuclei 89% of the tumor samples had an H-score at least equal to 2. Treatment type and metastatic status were predictive of overall survival (respectively, p = 0.003 and p = 0.005). Higher expression of ERCC1 tended to be correlated with longer overall survival (p = 0.08). Conclusions: Our observations are at variance with recently published data about the predictive role of ERCC1 (Handra Luca CCR 2008). Overexpression of ERCC1 has also been associated with better outcome of operated NSCLC. Such differences may be due to inherent biological differences between study populations and certainly attributable to different roles of ERCC1 through oncogenesis.These controversial correlative results among studies and the intense and diffuse patterns of ERCC1 expression might also indicate a central role of ERCC1 in HNSCC oncogenesis and then provide a potential target. Further investigations about the role and predictive value of ERCC1 protein in anticancer treatments including cisplatin are warranted. No significant financial relationships to disclose.


Sign in / Sign up

Export Citation Format

Share Document